Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study

Autor: Caroline Sindet-Pedersen, Jannik Langtved Pallisgaard, Laila Staerk, Jeffrey S. Berger, Morten Lamberts, Christian Torp-Pedersen, Gunnar H. Gislason, Jonas Bjerring Olesen

Publikováno v: Scientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)

Abstract Danish nationwide registries were used to investigate temporal trends in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K antagonists (VKA) in patients with venous thromboembolism (VTE). Patients treated with one of the N

Externí odkaz: https://doaj.org/article/a356c7fa19f545c8a9a069f90130ab95

Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study

Autor: Michelle T. Long, Xiaoyan Yin, Martin G. Larson, Patrick T. Ellinor, Steven A. Lubitz, David D. McManus, Jared W. Magnani, Laila Staerk, Darae Ko, Robert H. Helm, Udo Hoffmann, Raymond T. Chung, Emelia J. Benjamin

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 5 (2017)

BackgroundObesity is an important risk factor for nonalcoholic fatty liver disease and atrial fibrillation (AF). Less is known about the relations between nonalcoholic fatty liver disease and AF. We sought to evaluate the association between fatty li

Externí odkaz: https://doaj.org/article/3b86e45e2ab14e98ba56d23df1a7038a

Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study

Autor: Anna Gundlund, Jonas Bjerring Olesen, Laila Staerk, Christina Lee, Jonathan P. Piccini, Eric D. Peterson, Lars Køber, Christian Torp‐Pedersen, Gunnar H. Gislason, Emil Loldrup Fosbøl

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 11 (2016)

BackgroundWe examined all‐cause mortality and long‐term thromboembolic risk (ischemic stroke, transient ischemic attack, systemic thromboembolism) in patients with and without familial atrial fibrillation (AF). Methods and ResultsUsing Danish nat

Externí odkaz: https://doaj.org/article/d977fec20f944ca28f4ceeb7309d2551

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.

Autor: Jannik Langtved Pallisgaard, Tommi Bo Lindhardt, Morten Lock Hansen, Anne-Marie Schjerning, Jonas Bjerring Olesen, Laila Staerk, Christian Torp-Pedersen, Gunnar Hilmar Gislason

Publikováno v: PLoS ONE, Vol 10, Iss 10, p e0141377 (2015)

Cardioversion can rapidly and effectively restore sinus rhythm in patients with persistent atrial fibrillation. Since 2011 dabigatran has been available as an alternative to warfarin to prevent thromboembolic events in patients with non-valvular atri

Externí odkaz: https://doaj.org/article/1d3a6b81da694de18b0a4c88735130af

All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease

Autor: Jonas Bjerring Olesen, Laila Staerk, Jarl Emanuel Strange, Erik Lerkevang Grove, Caroline Sindet-Pedersen, Gunnar Gislason, Thomas A. Gerds, Christian Torp-Pedersen

Publikováno v: Strange, J E, Sindet-Pedersen, C, Staerk, L, Grove, E L, Gerds, T A, Torp-Pedersen, C, Gislason, G H & Olesen, J B 2021, ' All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease ', European Heart Journal-Cardiovascular Pharmacotherapy, vol. 7, no. FI1, pp. f93–f100 . https://doi.org/10.1093/ehjcvp/pvaa011
Strange, J E, Sindet-Pedersen, C, Staerk, L, Grove, E L, Gerds, T A, Torp-Pedersen, C, Gislason, G H & Olesen, J B 2021, ' All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease ', European heart journal. Cardiovascular pharmacotherapy, vol. 7, no. FI1, pp. f93-f100 . https://doi.org/10.1093/ehjcvp/pvaa011
Strange, J E, Sindet-Pedersen, C, Staerk, L, Grove, E L, Gerds, T A, Torp-Pedersen, C, Gislason, G H & Olesen, J B 2021, ' All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease ', European Heart Journal-Cardiovascular Pharmacotherapy, vol. 7, no. FI1, pvaa011, pp. f93-f100 . https://doi.org/10.1093/ehjcvp/pvaa011

Aims To compare the risk of all-cause mortality, stroke, and bleeding in patients with atrial fibrillation (AF) and valvular heart disease (VHD) treated with vitamin K antagonist (VKA) or factor Xa-inhibitors (FXa-I; rivaroxaban and apixaban). Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7c05593022dbff50b70d789ea8c59b
https://vbn.aau.dk/da/publications/e65339c6-b057-4454-ae69-9a01f7bf18a3